The company is using a ‘lab-in-the-loop’ process to advance the drug discovery process, and stated that opening a new lab space represents a step forward on its path to ‘transform drug discovery’.
Children in Europe living with HIV are on course to receive a once-daily treatment after EU marketing authorisation (EMA) was given to ViiV Healthcare’s Triumeq PD.
A survey conducted to understand whether supply issues over amoxicillin have persisted in the US found that an overwhelming majority of pharmacists are still struggling to source the commonly-used antibiotic.
The company announces an addition to its portfolio of drug delivery devices, with its pen injector platform that is described as being more affordable to produce.
Hataali has introduced a new version of its blockchain-based advanced therapy platform to address one of the key supply chain challenges faced by contract manufacturers and pharma companies today.
The company announces the submission of a 510(k) premarket notification application for its investigational inhaled nitric oxide delivery system for its INOmax gas product.
Researchers from the University of California San Diego tested whether algae could improve the delivery of antibiotics to treat cases of bacterial pneumonia.
TransCelerate BioPharma continues to work towards “bringing new medicines to patients faster”. We caught up with the organization’s CEO to hear about its main achievements over the past decade and learn about what comes next.
Pfizer and CytoReason have been partnered on artificial intelligence and machine learning technologies for drug discovery and development since 2019. The latest deal brings the companies closer.
Impel Pharmaceuticals’ Trudhesa treatment, paired with its Precision Olfactory Delivery system, reportedly shows promise to women suffering from the condition.
This month’s announcements of appointments, acquisitions, new hires, and other news include Standigm, Astellas Pharma, Trialbee, and other key companies.
The company has landed funding from the Bill and Melinda Gates Foundation for research and development on a prototype of a refillable contraceptive solution.
The company reports dosing of the first subject in a Phase IIa proof-of-concept study investigating a drug for an autism spectrum disorder related condition.
The group’s latest report glimpses inside the minds of pharma leaders, who are looking at a product’s full life-cycle development at the preclinical stage.
The pharmaceutical company has inked a strategic collaboration with the drug discovery firm, centering on uncovering novel targets in Alzheimer’s disease.
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
The pharmaceutical company has forged a partnership with the nanotechnology specialist to use nanoparticle tech and formulation to advance its products.
This month’s announcements of appointments, partnerships, expansions, and mergers include Curia, Thread, TFF Pharmaceuticals, and other notable companies.
A leader from pharmaceutical firm Astellas discusses how the company has put to use a discovery platform that combines human expertise, AI, and robotics.
This month’s announcements of launches, appointments, and partnerships includes Saama, COTA, Yourway, Eversana, Kindeva, and other notable industry companies.
Merck (MSD outside the US and Canada) is welcoming applications from early-stage biomedical start-ups for its newly launched Merck Digital Sciences Studio (MDSS): which seeks to support technologies for drug discovery and development.
In this first of a two-part series, an expert discusses various factors behind the DCT format’s rapid rise and likely longevity in the drug development arena.
This month’s announcements on new products, enhanced technology, partnerships, and more includes Eversana, Thermo Fisher Scientific, and other notable companies.
Efanesoctocog alfa is an investigational factor III therapy designed to prevent bleeds and bleeding episodes in patients diagnosed with the rare disorder.
This month’s announcements of awards, investments, executive appointment, and expansions include Javara, Thread, uMotif, Lonza, and other notable companies.
The drug company, which uses artificial intelligence to discover and advance repurposed drugs, is harnessing the technology to find a treatment for Crohn’s.
The approval is the first that the Food and Drug Administration has granted for a drug intended to treat eosinophilic esophagitis, a chronic immune disorder.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, has awarded a total of $577m to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
The digital therapeutics specialist has announced the last patient has ended participation in a study investigating a precision solution for hypertension.
The thin-film freezing specialist reports positive safety and pharmacokinetic data coming out of the Phase I trial of its niclosamide inhalation powder.
CPhI North America 2022 host city Philadelphia is set to become one of the world’s biggest cell and gene therapy manufacturing hubs. But it’s just one of many centers of innovation that are helping drive the US pharma and biopharma industry.
The agency has approved an expanded indication for Qelbree extended-release capsules to treat attention deficit hyperactivity disorder in younger patients.
The US agency has expanded its approval of Veklury to include use in pediatric patients 28 days and older who have tested positive for the COVID-19 virus.
The company’s Precision Olfactory Delivery technology, currently combined with its Trudhesa migraine treatment, reportedly facilitates high absorption rates.
